With a deep­er dis­count in place, NICE now ready to en­dorse use of No­var­tis' Kym­ri­ah in adult lym­phoma pa­tients

Looks like No­var­tis has made nice with UK’s NICE. The cost-ef­fec­tive­ness watch­dog re­versed its Sep­tem­ber po­si­tion to en­dorse the Swiss drug­mak­er’s CAR-T ther­a­py, Kym­ri­ah, in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER